Prematurity Predicts Neurodevelopmental Outcomes in Congenital Heart Disease
Abstract Body (Do not enter title and authors here): Background: Neurodevelopmental (ND) impairment is common in both prematurity and congenital heart disease (CHD). Preterm infants with CHD may have a “double hit,” with worse ND impairments than seen in prematurity or CHD alone. We analyzed whether gestational age (GA) at delivery predicted ND outcomes in children with CHD. Methods: We performed a single-institution retrospective study of children who underwent infant heart surgery from 2007-2020 and returned for ND evaluation after discharge. Exclusion criteria were 1) trisomy 21 and 2) PDA ligation alone. The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) assessed ND between ages 6-40 months. Patients were stratified into 4 GA groups: very/moderately preterm (≤33 weeks), late-preterm (34-36 weeks), early-term (37-38 weeks) or term/post-term (≥39 weeks). Hierarchical linear regression evaluated potential predictors of Bayley-III composite scores including GA category, demographic, medical, and surgical variables. Results: Among 1350 infants, 513 (38%) had a Bayley-III at median age 28 months [IQR 19, 34]. Of these, 448 (87%) were full-term and 65 (13%) preterm. In univariate analyses, children born preterm vs. full term had lower Bayley-III cognitive, language, and motor scores, explaining from 2.4% (language) to 6.2% (motor) of the variance in Bayley composite scores. In the final models, GA remained a strong independent predictor of motor and cognitive scores. Children with GA ≤33 weeks had the worst outcomes, with age-adjusted cognitive and motor composite scores 11 and 15 points lower, respectively, than those of term infants (Figure). Other significant risk factors included lower primary caregiver education, Black race, longer hospital length of stay, and genetic diagnosis. These models ultimately explained 17-26% of the variance in Bayley scores, with the highest explained variance in the motor domain. Conclusions: Adjusting for other patient and medical factors, preterm infants with CHD have worse cognitive and motor outcomes; risk is highest in those born at ≤33 weeks. Further work is needed to identify potentially modifiable factors to tailor prenatal, postnatal and perioperative care of infants with CHD born prematurely.
Katz, Jenna
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Gauvreau, Kimberlee
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Butler, Samantha
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Sadhwani, Anjali
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Levy, Phillip
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Kaza, Aditya
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Nathan, Meena
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Newburger, Jane
( Boston Children's Hospital
, Boston
, Massachusetts
, United States
)
Author Disclosures:
Jenna Katz:DO NOT have relevant financial relationships
| Kimberlee Gauvreau:DO NOT have relevant financial relationships
| Samantha Butler:No Answer
| Anjali Sadhwani:No Answer
| Phillip Levy:DO have relevant financial relationships
;
Consultant:Michigan Public Health Institute:Active (exists now)
; Consultant:People.Health:Active (exists now)
; Ownership Interest:UltraSight Medical:Active (exists now)
; Consultant:UltraSight Medical:Active (exists now)
; Consultant:Tosoh Bioscience, Inc:Active (exists now)
; Consultant:Siemens:Past (completed)
; Consultant:Roche Diagnostics:Past (completed)
; Consultant:Quidel Ortho:Active (exists now)
; Consultant:Pathfast:Active (exists now)
; Ownership Interest:Mespere:Active (exists now)
; Consultant:Moderna:Past (completed)
; Consultant:Cardionomics:Past (completed)
; Consultant:Beckman Coulter:Active (exists now)
; Consultant:BTG Speciality Pharmaceuticals:Active (exists now)
; Consultant:Bayer Healthcare Pharmaceuticals:Past (completed)
| Aditya Kaza:DO NOT have relevant financial relationships
| Meena Nathan:No Answer
| Jane Newburger:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Pfizer:Active (exists now)
; Royalties/Patent Beneficiary:UpToDate:Active (exists now)
; Other (please indicate in the box next to the company name):Daichii Sankyo (trial Steering Committee):Past (completed)
; Other (please indicate in the box next to the company name):BMS (Chair of DSMB for pediatric mavacamten trial):Active (exists now)
; Other (please indicate in the box next to the company name):Novartis (Chair, Independent EAC):Past (completed)
; Other (please indicate in the box next to the company name):BMS (Chair, Independent EAC):Active (exists now)
; Other (please indicate in the box next to the company name):Pfizer (Chair Independent EAC):Active (exists now)